Stock Market Today, October 5, 2026: Nasdaq Leads Rally as Tech Ignores Bond-Market Side-Eye -( $AMWL $AZN $DOCS $EPRX $LPL $MODD $NVDA $SER $SMMT $SPCX $TSLA $TSM )

Monday, October 5, 2026

U.S. stocks closed broadly higher Monday, with technology leadership pushing the Nasdaq Composite to the day’s strongest gain and lifting the S&P 500 to a solid advance. The Dow Jones Industrial Average also finished modestly higher, while small-cap stocks, long-term Treasury yields, and volatility moved upward.

Market Close

Market Commentary

Monday’s session reflected a clear rotation toward growth and technology stocks. The Nasdaq Composite gained 1.05%, outpacing the S&P 500’s 0.66% advance and the Dow’s more restrained 0.18% gain. The performance gap suggests investors continued to favor higher-growth technology, artificial-intelligence, semiconductor, and digital-infrastructure themes rather than broadly bidding up every corner of the market. The Russell 2000 rose 0.50%, indicating that market participation was wider than the Dow’s narrow gain alone might imply. Still, large-cap growth remained the central driver of risk appetite, with the Nasdaq’s 286.45-point move providing the session’s strongest directional signal. The S&P 500 finished at 7,773.05, while the Dow settled at 51,267.90 and the Nasdaq Composite closed at 27,477.31. Those index levels underscore the market’s continued resilience going into the early stages of third-quarter earnings season.

Macroeconomic Report Commentary

The market advanced despite a further increase in the 10-year Treasury yield, which rose to 5.31%. Higher long-term yields generally raise the discount rate applied to future corporate earnings, making the day’s technology-led rally notable. Investors appeared willing to look through the immediate rate pressure, at least temporarily, in favor of earnings growth expectations and continued enthusiasm around AI-related capital spending.

The key macroeconomic tension remains intact:

• Growth remains supportive: Equity investors continue to price in enough economic durability to support corporate earnings and risk assets.
• Rates remain restrictive: A 5.31% 10-year yield keeps borrowing costs elevated for consumers, businesses, commercial real estate, and more indebted companies.
• Inflation remains a watch item: Gold finished marginally higher at $4,166.20, while crude oil declined 2.10% to $89.20 per barrel. Lower oil prices may offer short-term relief to inflation expectations, although energy remains well above levels that would eliminate price-pressure concerns.
• Risk appetite is constructive but measured: The VIX rose 1.31% to 15.51 even as stocks rallied, suggesting that investors were participating in the advance without fully abandoning hedging activity.

The combination of rising yields and higher equities suggests investors are not yet treating the bond market as a decisive warning signal. However, continued upward pressure in yields could eventually test valuations, especially in long-duration growth companies whose share prices depend heavily on earnings projected years into the future.

Corporate and Sector Focus

Technology and AI-related stocks remained central to the market narrative. NVIDIA Corporation (NASDAQ: NVDA) and Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) continued to represent major focal points for investors seeking exposure to AI computing, advanced semiconductor manufacturing, and global data-center spending. Investor attention also remained elevated around alternative AI-computing platforms and the broader buildout of computing, networking, and optical infrastructure. SpaceX (NASDAQ: SPCX) attracted fresh attention after a bullish Morgan Stanley assessment, with the report highlighting potential upside tied to future milestones in launch services, Starship development, satellite connectivity, and defense-adjacent opportunities. Tesla, Inc. (NASDAQ: TSLA) also remained part of the AI-and-manufacturing conversation through ongoing discussion of potential semiconductor capacity initiatives associated with Elon Musk’s business ecosystem. In healthcare, AstraZeneca PLC (NASDAQ: AZN) outlined the potential strategic importance of its investment and collaboration with Summit Therapeutics Inc. (NASDAQ: SMMT). The companies are evaluating cancer-treatment combinations involving Summit’s ivonescimab and AstraZeneca’s antibody-drug conjugate pipeline, illustrating the continued industry focus on next-generation oncology platforms, targeted therapies, and combination regimens.

A Takeaway

Monday’s market action was constructive: all four major U.S. stock benchmarks gained, with the Nasdaq’s 1.05% advance confirming continued leadership from growth and technology. Falling crude oil prices supported sentiment, while the Russell 2000’s gain pointed to broader participation beyond mega-cap equities. However, the market’s next test is whether earnings growth and economic resilience can continue to outweigh elevated yields. Investors will be watching third-quarter corporate results, forward guidance, bond-market moves, inflation data, and Federal Reserve communications for evidence that today’s technology-led strength can broaden into a more durable market advance.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.72, +2.66%.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $2.04, +4.08%) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $11.25) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

HPP announced (Oct. 5) that its operating partnership, Hudson Pacific Properties, L.P. (the “Company”), has commenced an offer to purchase for cash (the “Tender Offer”) up to a combined aggregate principal amount of $200,000,000 (the “Aggregate Maximum Tender Offer Amount”) of the Company’s outstanding 3.950% Senior Notes due 2027 (the “2027 Notes”) and 5.950% Senior Notes due 2028 (the “2028 Notes” and together with the 2027 Notes, the “Notes” and each a “Series” of Notes) as shown in the linked story, subject to the Allocation Procedures, including the Proration Factor (each as defined below). The Company is offering to purchase $100,000,000 aggregate principal amount of each Series of Notes (the “Target Allocation”).

HPP turned in a quarter ( Aug. 5) that suggests the office malaise is not over, but it may finally be meeting resistance. Revenue came in above Wall Street’s expectations, occupancy moved higher for a fourth straight quarter, and management raised full-year guidance, a combination that does not make for a triumphant victory lap, but it does make for a more credible turnaround narrative. Learn more.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.75, +6.98%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the ongoing RESOLVE study. For a chronic disease in which swallowing can become a calculated exercise rather than an automatic human function, durability is more than a tidy line on a clinical slide. It is central to the value proposition. The latest data suggest Eupraxia’s localized, extended-release approach may be building toward a differentiated position in a market already led by a formidable incumbent: Sanofi S.A. (NASDAQ: SNY) and its biologic franchise, Dupixent. The clinical data remain early, open-label, and small in patient count, biotech investors should keep both feet on the ground, even when the data seem to float, but the one-year observations give EPRX a meaningful argument for continued investor attention ahead of interim randomized Phase 2b results expected in December 2026.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.30, +13.30%), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026 (8:30am PT / 11:30 am ET). You may watch the event video below now if you missed it below now.

MODD announced (Aug. 3) plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company’s capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.

MODD recently (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.10) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $2.58), a leading China-based beauty group, delivered the sort of quarter that can make a turnaround investor sit up straighter: reported revenue grew, its strategically important skincare operation accelerated sharply, and the company is increasingly built around clinical and premium brands rather than a pure color-cosmetics play. The results are not yet a victory lap, losses widened and third-quarter guidance is cautious, but YSG’s transformation is beginning to look less like a cosmetic touch-up and more like a genuine renovation.

YSG announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $28.58, +2.33%) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

DOCS announced (Sept. 22) that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform. As part of the launch, Doximity is publishing a new open-source benchmark for measuring clinical-grade AI. Called Bedside Bench, the benchmark has been built to test AI’s ability to be a trusted partner to doctors where it matters most: at the bedside.

Doximity, Inc. (NYSE: DOCS) announced (Aug. 6) results of its fiscal 2027 first quarter ended June 30, 2026. Jeff Tangney, co-founder and CEO of Doximity, “We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

• Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.
• Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.
• Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.
• Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.
• Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

• Revenue between $170 million and $171 million.
• Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

• Revenue between $671 million and $681 million.
• Adjusted EBITDA between $309 million and $329 million.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (NYSE: SOC, $3.47) provided (Sept. 28) the following operational update focused on the pending restart of Platform Hondo, ongoing Las Flores Canyon Midstream Processing Facility (“LFC”) upgrades, and the current status of oil midstream and marketing. 1. Platform Hondo Platform Hondo reconstruction and internal operational commissioning are complete. Over the course of Sable’s recommissioning period, Sable has modernized Platform Hondo from a manually controlled platform to one with up-to-date technology and safety standards.
2. Sable has been working productively with the Marine Minerals Administration (the “MMA”) throughout Platform Hondo recommissioning and anticipates the MMA’s final review and approval of the Platform Hondo instrumentation, control, and safety commissioning submission in October 2026. 3. Instrumentation, controls, and additional safety testing and commissioning are expected in October 2026. Sable continues to prioritize the safe and sustainable long-term operational viability of Platform Hondo. 4. Sable plans to accelerate and complete 4 additional Perforation Addition (“Perf Add”) operations on Platform Hondo ahead of an expected Q4 2026 platform restart. 5. The 4 additional Perf Adds are expected to result in completed Perf Adds on 9 of the 15 production wells on Platform Hondo ahead of restart as opposed to the previously expected 5 completed Perf Adds pre-restart. 6. Each Perf Add is estimated to produce an incremental ~600 barrels of oil per day to the base well production at a cost of approximately $800,000 per operation. Learn more.

Nvidia (NVDA, $238.90, +2.12%)

NVIDIA Corp. (NASDAQ: NVDA). AM Intelligence (“AMI”), the AI infrastructure platform set up by Promoters of Greenko, announced (Oct. 5) two further firm and binding orders for 20,000 NVIDIA Rubin GPUs, to be deployed as NVIDIA Vera Rubin NVL72 rack-scale systems. Building on its first AI factory in Hyderabad, the expansion is designed to give cloud providers, enterprises and AI developers access to large-scale computing capacity closer to where they build and deploy AI.

NVDA recently has seemingly has given many a two-part bullish signal: a record-sized $150 billion increase to its share-repurchase authorization and a new AI-agent safety platform aimed at making autonomous software more secure for enterprise deployment. The combination suggests a company using extraordinary financial strength not merely to reward shareholders, but to expand its influence from AI computing into the governance, security and operating layer of the AI economy. The timing is notable. Markets are beginning the week with a cautiously constructive tone, even as investors brace for jobs, inflation and manufacturing data that could reset the outlook for interest rates. In that environment, NVIDIA is making a familiar but potent argument: its AI franchise is generating enough cash to finance innovation, deepen its ecosystem and return meaningful capital to shareholders, all at once. That is not an everyday corporate trick. It is closer to juggling bowling balls while also building the bowling alley.

The Sources

1. Yahoo Finance Stock Market Today: Dow, S&P 500 and Nasdaq Rise as Tech Rallies
2. Yahoo Finance SpaceX Jumps to Highest Close Since June on Bullish Morgan Stanley Call
3. CNBC SpaceX Stock Climbs to Highest Level Since June
4. CNBC Stock Futures Are Flat as Investors Grapple With Higher Yields and Await Fed Minutes
5. CNBC AstraZeneca CEO Says Summit Drug Could Drive Future Cancer Combinations